Most researchers looking for CJC-1295 in Chūō rapidly learn that local retail options are virtually absent. This online-only market structure is a genuine benefit for researchers — top vendors compete on lab-verified purity in ways local stores never could. Separating genuine research-grade CJC-1295 from the rest of the market comes down to three things: an HPLC chromatogram confirming ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. This guide gives Chūō researchers the framework to verify sourcing options methodically and source verified-quality CJC-1295 with confidence.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Chūō comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Vetting CJC-1295 vendors starts with the COA: request the batch-specific certificate before placing an order, not after. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. Negative indicators in CJC-1295 vendor evaluation: prices far under typical market pricing, vague sourcing information, no community presence, and COAs that lack endotoxin data. For Chūō researchers making a first CJC-1295 purchase: verify the vendor against this framework, begin with a small order, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Chūō
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and restricted human research data. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — equivalent to 25mcg per unit on an insulin syringe. Verify the endotoxin level in your CJC-1295 batch COA before any injectable research application — look for results reported in endotoxin units per mg or mL and confirm they fall within appropriate thresholds. Researchers running multi-compound protocols with CJC-1295 should review the available literature for documented interactions before beginning combination research.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
